FENC
Fennec Pharmaceuticals Inc.
$9.06
+$0.08(+0.89%)
60
Overall
40
Value
90
Tech
52
Quality
Market Cap
$236.01M
Volume
372.70K
52W Range
$5.65 - $10.45
Target Price
$15.57
Order:
Income Statement
| Metric | Trend | Chart | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $1.5M | $21.3M | $29.6M | $44.6M | ||
| Total Revenue | $1.5M | $21.3M | $47.5M | $44.6M | ||
| COST OF GOODS SOLD | ||||||
| Cost of Revenue | $86.0K | $1.3M | $3.2M | $3.8M | ||
| GROSS PROFIT | ||||||
| Gross Profit | $1.4M | $20.0M | $44.4M | $40.9M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $24.2M | $33.1M | $41.9M | $47.2M | ||
| Research & Development | $3.5M | $56.0K | $307.0K | $250.0K | ||
| Research Expense | $3.5M | $56.0K | $307.0K | $250.0K | ||
| Selling, General & Administrative | $20.5M | $32.7M | $41.5M | $46.9M | ||
| Selling & Marketing Expenses | $2.8M | $12.1M | $18.4M | $18.6M | ||
| General & Administrative Expenses | $17.7M | $20.6M | $23.1M | $28.3M | ||
| Depreciation & Amortization | $149.0K | $287.0K | $89.0K | $64.0K | ||
| Depreciation & Amortization | $149.0K | $287.0K | $89.0K | $64.0K | ||
| Amortization | $149.0K | $287.0K | $89.0K | $64.0K | ||
| OPERATING INCOME | ||||||
| Operating income | $-22.7M | $-13.1M | $2.5M | $-6.3M | ||
| EBITDA | $-22.6M | $-12.4M | $4.3M | $-7.5M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $978.0K | $3.4M | $4.1M | $2.1M | ||
| Intinc | $195.0K | $441.0K | $1.7M | $787.0K | ||
| Net Non-Operating Interest Income/Expense | $-783.0K | $-3.0M | $-2.4M | $-1.3M | ||
| Other Income/Expense | $184.0K | $39.0K | $81.0K | $2.0M | ||
| Other Special Charges | -- | -- | -- | $-2.0M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-22.7M | $-12.7M | $4.2M | $-7.6M | ||
| Pre-Tax Income | $-23.7M | $-16.1M | $93.0K | $-9.6M | ||
| INCOME TAX | ||||||
| Tax Provision | -- | -- | $365.0K | $106.0K | ||
| NET INCOME | ||||||
| Net Income | $-23.7M | $-16.1M | $-272.0K | $-9.7M | ||
| Net Income (Continuing Operations) | $-23.7M | $-16.1M | $-272.0K | $-9.7M | ||
| Net Income (Discontinued Operations) | $-23.7M | $-16.1M | $-272.0K | $-9.7M | ||
| Net Income (Common Stockholders) | $-23.7M | $-16.1M | $-272.0K | $-9.7M | ||
| Normalized Income | $-17.4M | $-11.8M | $92.1K | $-9.5M | ||
| TOTALS | ||||||
| Total Expenses | $24.3M | -- | -- | $51.0M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $26.3M | $265.7M | $27.3M | $28.6M | ||
| Average Shares Outstanding (Diluted) | $26.3M | $26.6M | $27.3M | $28.6M | ||
| Shares Outstanding | $34.5M | $34.5M | $27.5M | $34.2M | ||
| Basic EPS | $-0.90 | $-0.06 | $-0.02 | $-0.34 | ||
| Basic EPS (Continuing Operations) | $-0.90 | $-0.06 | $-0.02 | $-0.34 | ||
| Diluted EPS | $-0.90 | $-0.60 | $-0.02 | $-0.34 | ||
| Diluted EPS (Continuing Operations) | $-0.90 | $-0.60 | $-0.02 | $-0.34 | ||
| OTHER METRICS | ||||||
| Other Costof Revenue | $86.0K | $1.3M | $3.2M | $3.8M | ||
| Other Gand A | $17.7M | $20.6M | $23.1M | $28.3M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FENC | $9.06 | +0.9% | 372.70K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Fennec Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW